Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
Resolution Bioscience is a fast-growing, innovative leader in next-generation sequencing (NGS)-based oncology solutions.
Combination brings together Resolution Bioscience’s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent’s leadership in tissue-based companion diagnostics and global commercial and regulatory scale.
Furthers Agilent’s participation in fast-growing NGS technologies for precision oncology, expanding Agilent’s addressable market by $3 billion in 2025 with that figure estimated to double by 2030. Read more